Cancer Genetics Complete::IO Immuno-Oncology Panel

Cancer Genetics has launched a new multiplex flow cytometry panel for use in cancer immunotherapy assessment, patient monitoring following treatment, and patient selection and stratification for clinical trials. The Complete::IO assay can help characterize the immune repertoire, immune cell populations, and the tumor microenvironment, the firm said. It detects up to 10 markers on each cell, enabling identification of rare immune cells, including central memory cells, effector cells, effector memory cells, naive CD4+ and CD8+ T cells, regulatory T and B cells, natural killer cells, and plasmacytoid dendritic cells.